Segments of business and geographic areas (Tables)

3 Months Ended

Mar. 29, 2026


	Fiscal First Quarter Ended
(Dollars in Millions)	March 29, 2026	March 30, 2025	Percent Change

INNOVATIVE MEDICINE
Oncology
U.S.	$3,615	3,013	20.0	%
International	3,358	2,664	26.0
Worldwide	6,973	5,678	22.8
DARZALEX
U.S.	2,208	1,829	20.7
International	1,756	1,409	24.7
Worldwide	3,964	3,237	22.5
CARVYKTI
U.S.	433	318	36.2
International	164	51	*
Worldwide	597	369	62.1
TECVAYLI
U.S.	127	105	20.6
International	74	46	63.1
Worldwide	202	151	33.5
TALVEY
U.S.	101	68	48.5
International	51	18	*
Worldwide	152	86	76.7
RYBREVANT/ LAZCLUZE
U.S.	175	113	55.1
International	82	28	*
Worldwide	257	141	82.7
ERLEADA
U.S.	342	292	17.3
International	607	479	26.7
Worldwide	949	771	23.1
IMBRUVICA
U.S.	143	235	(39.1)
International	517	474	9.1
Worldwide	660	709	(6.9)


	Fiscal First Quarter Ended
(Dollars in Millions)	March 29, 2026	March 30, 2025	Percent Change
OTHER ONCOLOGY(1)
U.S.	85	54	58.8
International	106	160	(33.9)
Worldwide	192	214	(10.6)
Immunology
U.S.	1,855	2,196	(15.5)
International	1,524	1,510	0.9
Worldwide	3,380	3,707	(8.8)
TREMFYA
U.S.	1,042	599	73.9
International	566	356	58.9
Worldwide	1,608	956	68.3
SIMPONI / SIMPONI ARIA
U.S.	269	292	(7.8)
International	378	366	3.0
Worldwide	647	659	(1.7)
REMICADE
U.S.	269	314	(14.4)
U.S. Exports	18	10	78.6
International	136	143	(4.8)
Worldwide	422	467	(9.5)
STELARA
U.S.	220	981	(77.6)
International	435	644	(32.4)
Worldwide	656	1,625	(59.7)
OTHER IMMUNOLOGY
U.S.	38	1	*
International	9	0	*
Worldwide	46	1	*
Neuroscience
U.S.	1,494	968	54.3
International	681	679	0.3
Worldwide	2,175	1,647	32.0
SPRAVATO
U.S.	406	276	47.0
International	61	43	42.4
Worldwide	468	320	46.4
CAPLYTA(2)
U.S.	270	—	*
International	—	—	—
Worldwide	270	—	*


	Fiscal First Quarter Ended
(Dollars in Millions)	March 29, 2026	March 30, 2025	Percent Change
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
U.S.	758	625	21.2
International	280	277	1.1
Worldwide	1,038	903	15.0
CONCERTA / methylphenidate
U.S.	22	38	(43.4)
International	115	110	4.3
Worldwide	136	148	(8.0)
OTHER NEUROSCIENCE
U.S.	38	28	32.6
International	224	248	(9.7)
Worldwide	262	277	(5.4)
Pulmonary Hypertension (PH)
U.S.	831	744	11.7
International	304	281	8.2
Worldwide	1,135	1,025	10.7
UPTRAVI
U.S.	385	365	5.4
International	98	86	14.3
Worldwide	483	451	7.1
OPSUMIT/OPSYNVI
U.S.	433	363	19.3
International	172	159	8.7
Worldwide	606	522	16.1
OTHER PULMONARY HYPERTENSION
U.S.	12	15	(21.1)
International	34	37	(8.3)
Worldwide	46	52	(12.1)
Infectious Diseases (ID)
U.S.	342	315	8.6
International	547	487	12.2
Worldwide	889	802	10.8
EDURANT / rilpivirine
U.S.	7	8	(13.1)
International	402	350	14.8
Worldwide	409	358	14.1
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
U.S.	334	305	9.5
International	109	98	11.2
Worldwide	443	403	10.0


	Fiscal First Quarter Ended
(Dollars in Millions)	March 29, 2026	March 30, 2025	Percent Change
OTHER INFECTIOUS DISEASES
U.S.	1	2	(56.9)
International	36	39	(8.3)
Worldwide	37	41	(10.4)
Cardiovascular / Metabolism / Other (CVM)
U.S.	734	855	(14.2)
International	142	158	(10.4)
Worldwide	876	1,013	(13.6)
XARELTO
U.S.	642	690	(7.0)
International	—	—	—
Worldwide	642	690	(7.0)








OTHER
U.S.	91	165	(44.5)
International	142	158	(10.4)
Worldwide	233	323	(27.8)
Total PH, ID, CVM
U.S.	1,907	1,914	(0.4)
International	993	926	7.1
Worldwide	2,899	2,840	2.1

TOTAL INNOVATIVE MEDICINE
U.S.	8,871	8,092	9.6
International	6,555	5,781	13.4
Worldwide	15,426	13,873	11.2

MEDTECH








Cardiovascular
U.S.	1,399	1,261	10.9
International	978	842	16.1
Worldwide	2,377	2,103	13.0
ELECTROPHYSIOLOGY
U.S.	736	684	7.6
International	753	638	18.0
Worldwide	1,489	1,323	12.6
ABIOMED
U.S.	389	339	14.5
International	100	81	23.5
Worldwide	488	420	16.3
SHOCKWAVE
U.S.	242	206	17.8
International	63	52	21.3
Worldwide	305	258	18.5


	Fiscal First Quarter Ended
(Dollars in Millions)	March 29, 2026	March 30, 2025	Percent Change
OTHER CARDIOVASCULAR
U.S.	32	32	0.7
International	62	72	(13.4)
Worldwide	94	103	(9.1)
Surgery
U.S.	1,046	1,002	4.4
International	1,465	1,394	5.1
Worldwide	2,511	2,396	4.8
ADVANCED
U.S.	477	457	4.2
International	646	616	4.9
Worldwide	1,123	1,073	4.6
GENERAL
U.S.	569	544	4.5
International	819	778	5.2
Worldwide	1,388	1,323	4.9
Vision
U.S.	579	566	2.4
International	785	713	10.1
Worldwide	1,365	1,279	6.7
CONTACT LENSES / OTHER
U.S.	468	452	3.7
International	501	467	7.2
Worldwide	969	919	5.5
SURGICAL
U.S.	111	114	(2.9)
International	285	246	15.6
Worldwide	396	361	9.7
Orthopaedics*
U.S.	1,435	1,384	3.7
International	948	857	10.6
Worldwide	2,383	2,241	6.3
HIPS
U.S.	277	263	5.2
International	159	146	8.9
Worldwide	436	409	6.5
KNEES
U.S.	239	231	3.3
International	181	158	14.6
Worldwide	420	389	7.9


	Fiscal First Quarter Ended
(Dollars in Millions)	March 29, 2026	March 30, 2025	Percent Change
TRAUMA
U.S.	532	502	6.1
International	301	270	11.4
Worldwide	833	772	8.0
SPINE, SPORTS & OTHER
U.S.	387	388	(0.1)
International	307	283	8.4
Worldwide	694	671	3.5

TOTAL MEDTECH
U.S.	4,459	4,213	5.9
International	4,177	3,807	9.7
Worldwide	8,636	8,020	7.7

WORLDWIDE
U.S.	13,330	12,305	8.3
International	10,732	9,588	11.9
Worldwide	$24,062	21,893	9.9	%

* Percentage greater than 100% or not meaningful

(1) Includes the sales of ZYTIGA which were previously disclosed separately

(2) Acquired with Intra-Cellular Therapies on April 2, 2025

Operating Profit by Segment of Business


	Fiscal First Quarter Ended
(Dollars in Millions)	March 29, 2026			March 30, 2025
	Innovative Medicine(1)	MedTech(2)	Total	Innovative Medicine(1)	MedTech(2)	Total
Sales to customers	$15,426	8,636		13,873	8,020
Cost of products sold	4,390	3,701		4,020	3,326

Selling, marketing and administrative	2,918	2,906		2,261	2,656
Research and development expense	2,813	714		2,548	677
Other segment items (3)	(12)	76		(166)	(60)
Segment income before tax	$5,317	1,239	6,556	5,210	1,421	6,631
(Income)/Expense not allocated to segments (4)			566			(7,000)
Earnings before provision for taxes on income			$5,990			$13,631

(1) Innovative Medicine includes:

•Intangible amortization expense of $0.8 billion and $0.6 billion in the fiscal first quarters of 2026 and 2025, respectively.

(2) MedTech includes:

•Intangible amortization expense of $0.5 billion in both the fiscal first quarters of 2026 and 2025.

•Orthopaedics Separation related charge of $0.1 billion in the fiscal first quarter of 2026.

•Acquisition and integration related expense of $0.1 billion in the fiscal first quarter of 2025, primarily related to Shockwave.

(3) Other segment items for each reportable segment include other income and expense (gains and losses on divestitures and gains and losses on sale of assets), restructuring activities and impairment charges related to in-process research and development

(4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal first quarter of 2026 includes charges for talc matters of $0.3 billion. The fiscal first quarter of 2025 includes approximately $7.0 billion related to the talc reserve reversal.


	Identifiable Assets
(Dollars in Millions)	March 29, 2026	December 28, 2025
Innovative Medicine	$78,118	78,057
MedTech	86,179	86,482
Total	164,297	164,539
General corporate (1)	36,597	34,671
Worldwide total	$200,894	199,210

(1)General corporate includes cash, cash equivalents, marketable securities and other corporate assets.


	Additions to Property, Plant & Equipment		Depreciation and Amortization
	Fiscal Three Months Ended
(Dollars in Millions)	March 29, 2026	March 30, 2025	March 29, 2026	March 30, 2025
Innovative Medicine	$508	276	$1,036	884
MedTech	509	480	903	836
Segments total	1,017	756	1,939	1,720
General corporate	32	39	65	52
Worldwide total	$1,049	795	$2,004	1,772

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas

Sales by geographic area


	Fiscal First Quarter Ended
(Dollars in Millions)	March 29, 2026	March 30, 2025	Percent Change
United States	$13,330	12,305	8.3	%
Europe	5,848	5,110	14.5
Western Hemisphere, excluding U.S.	1,293	1,167	10.8
Asia-Pacific, Africa	3,591	3,311	8.5
Total	$24,062	21,893	9.9	%